Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Fulgent Genetics, |
RCV002484072 | SCV002784319 | uncertain significance | Alagille syndrome due to a JAG1 point mutation; Tetralogy of Fallot; Deafness, congenital heart defects, and posterior embryotoxon; Charcot-Marie-Tooth disease, axonal, Type 2HH | 2022-05-08 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003284036 | SCV004005042 | uncertain significance | Cardiovascular phenotype | 2023-06-10 | criteria provided, single submitter | clinical testing | The p.R1169Q variant (also known as c.3506G>A), located in coding exon 26 of the JAG1 gene, results from a G to A substitution at nucleotide position 3506. The arginine at codon 1169 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Invitae | RCV003770226 | SCV004614932 | likely benign | Alagille syndrome due to a JAG1 point mutation | 2023-11-12 | criteria provided, single submitter | clinical testing | |
Molecular Genetics Laboratory, |
RCV001200019 | SCV001164097 | uncertain significance | Scoliosis; Pes planus; Aortic dilatation | 2020-02-28 | no assertion criteria provided | clinical testing |